Pub Date : 2023-05-20DOI: 10.25251/skin.7.supp.216
Teo Solelymani, B. Martin, Michael Tassavor
{"title":"The i31-gene expression profile test for cutaneous melanoma identifies patients with head and neck tumors who could forego sentinel lymph node biopsy","authors":"Teo Solelymani, B. Martin, Michael Tassavor","doi":"10.25251/skin.7.supp.216","DOIUrl":"https://doi.org/10.25251/skin.7.supp.216","url":null,"abstract":"","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45117168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-20DOI: 10.25251/skin.7.supp.203
Linda F. Stein Gold, MD,, Jonathan S. Weiss MD, Joseph F. Fowler MD, Adelaide A. Hebert MD, Jeffrey Sugarman MD
{"title":"Efficacy of a Novel Formulation of Betamethasone Dipropionate 0.05% Spray Versus Augmented Betamethasone Dipropionate 0.05% Lotion In Patients >= 18 Years of Age with Moderate Plaque Psoriasis: A Pooled Analysis","authors":"Linda F. Stein Gold, MD,, Jonathan S. Weiss MD, Joseph F. Fowler MD, Adelaide A. Hebert MD, Jeffrey Sugarman MD","doi":"10.25251/skin.7.supp.203","DOIUrl":"https://doi.org/10.25251/skin.7.supp.203","url":null,"abstract":"","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44594487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ariel Darnall, R. Olsen, D. Hamann, Sarah I. Estrada
Cutaneous metastases of prostate cancer are a rare entity and mimic many other common cutaneous conditions such as cellulitis, zosteriform lesions, and many others, making it easy to misdiagnose. Recognition of this condition is vital to prevent delays in treatment, as lesions usually appear in late stages of the disease and are associated with a high fatality rate. Here we describe a case of a 64-year-old man with a history of diffuse metastatic prostate carcinoma, who presented with a suprapubic rash that was initially diagnosed as cellulitis but was later determined to be cutaneous metastasis. Clinical characteristics of this metastasis and common dermal lesions with similar clinical presentations are discussed. Clinicians should be aware of the characteristics of this cutaneous metastasis and consider it when evaluating skin lesions that mimic soft tissue infections.
{"title":"Cutaneous Prostate Adenocarcinoma Masquerading as Cellulitis","authors":"Ariel Darnall, R. Olsen, D. Hamann, Sarah I. Estrada","doi":"10.25251/skin.7.3.13","DOIUrl":"https://doi.org/10.25251/skin.7.3.13","url":null,"abstract":"Cutaneous metastases of prostate cancer are a rare entity and mimic many other common cutaneous conditions such as cellulitis, zosteriform lesions, and many others, making it easy to misdiagnose. Recognition of this condition is vital to prevent delays in treatment, as lesions usually appear in late stages of the disease and are associated with a high fatality rate. Here we describe a case of a 64-year-old man with a history of diffuse metastatic prostate carcinoma, who presented with a suprapubic rash that was initially diagnosed as cellulitis but was later determined to be cutaneous metastasis. Clinical characteristics of this metastasis and common dermal lesions with similar clinical presentations are discussed. Clinicians should be aware of the characteristics of this cutaneous metastasis and consider it when evaluating skin lesions that mimic soft tissue infections.","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41840004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-20DOI: 10.25251/skin.7.supp.207
A. Paller, Keith R. Knapp, Breda Munoz, A. Claxton, S. Balu, Shannon Schnieder, L. Eichenfield
{"title":"Unmet Needs of Adolescents with Moderate to Severe Atopic Dermatitis in the TARGET DERM Registry","authors":"A. Paller, Keith R. Knapp, Breda Munoz, A. Claxton, S. Balu, Shannon Schnieder, L. Eichenfield","doi":"10.25251/skin.7.supp.207","DOIUrl":"https://doi.org/10.25251/skin.7.supp.207","url":null,"abstract":"","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43127569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mitchell Taylor, Amelia Pham, M. Clausen, Kamruz Darabi
We present the case of a 59-year-old female with multiple squamous neoplasms, including keratoacanthomas, well-differentiated squamous cell carcinomas, and prurigo nodules. The patient developed dozens of lesions progressively over the course of a few years. Keratoacanthomas can be challenging to distinguish from well-differentiated squamous cell carcinomas; this and the presence of numerous lesions poses a major challenge with diagnosing and managing this condition. The pathogenesis, challenges with diagnosis and management, and treatment regimens for eruptive keratoacanthomas are further discussed.
{"title":"Eruptive Keratoacanthoma in a 59-year-old Female with Chronic Kidney Disease: A Case Report and Review of Treatment Approaches","authors":"Mitchell Taylor, Amelia Pham, M. Clausen, Kamruz Darabi","doi":"10.25251/skin.7.3.2","DOIUrl":"https://doi.org/10.25251/skin.7.3.2","url":null,"abstract":"We present the case of a 59-year-old female with multiple squamous neoplasms, including keratoacanthomas, well-differentiated squamous cell carcinomas, and prurigo nodules. The patient developed dozens of lesions progressively over the course of a few years. Keratoacanthomas can be challenging to distinguish from well-differentiated squamous cell carcinomas; this and the presence of numerous lesions poses a major challenge with diagnosing and managing this condition. The pathogenesis, challenges with diagnosis and management, and treatment regimens for eruptive keratoacanthomas are further discussed.","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48775466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
C. Shope, L. Andrews, Ansley Devore, L. Wine Lee, C. Wagner
Background Melasma is a common, chronic skin condition of hyperpigmentation involving the appearance of symmetric and irregular light brown macules and patches, mainly on sun exposed skin of the head and neck. Though the pathogenesis is not fully understood, hyperfunctional melanocytes are known to deposit excess melanin in the epidermis and dermis. Known risk factors or triggers include genetic influence, hormonal influence, and ultraviolet radiation. Due to the avoidance of ultraviolet light, vitamin D supplementation is recommended. Due to known influence of vitamin D on the skin and the large prevalence of melasma in the public, the association between vitamin D and melasma will be examined further. Methods A retrospective review was performed utilizing the TriNetX platform to query de-identified patient data from the Medical University of South Carolina’s Electronic Health Record system over a 9-year period from January 2013 to May 2022. Calcidiol (25-hydroxy-vitaminD) was utilized as a surrogate for Vitamin D level. Statistical analyses were performed using Chi-square tests. Results Of 1,962 patients diagnosed with melasma, 840 had a serum calcidiol level measured following diagnosis. The majority of these patients were female (77%) and had an average age of 60.3 + 19.2 years. Melasma patients were most commonly Caucasian (81%), followed by African American (15%) and Hispanic or Latino (3%). Patients with melasma had an average serum calcidiol of 33.8 + 15.8 ng/mL (reference range: 25 – 80 ng/mL). This was significantly lower than comparison to 2,146 dermatology patients not diagnosed with melasma (36.8 + 15.8 ng/mL, p-value <0.0001%). Conclusion Vitamin D has been demonstrated to be critical in the skin, including differentiation and proliferation of melanocytes. Our results suggest that patients with melasma, who have significantly lower levels of serum vitamin D than their healthy counterparts, may benefit from vitamin D supplementation. Future studies investigating improvement in melasma symptoms following vitamin D supplementation are needed.
{"title":"Melasma is Associated with Lower Serum Vitamin D Concentrations as Compared to Healthy Controls","authors":"C. Shope, L. Andrews, Ansley Devore, L. Wine Lee, C. Wagner","doi":"10.25251/skin.7.3.5","DOIUrl":"https://doi.org/10.25251/skin.7.3.5","url":null,"abstract":"Background\u0000Melasma is a common, chronic skin condition of hyperpigmentation involving the appearance of symmetric and irregular light brown macules and patches, mainly on sun exposed skin of the head and neck. Though the pathogenesis is not fully understood, hyperfunctional melanocytes are known to deposit excess melanin in the epidermis and dermis. Known risk factors or triggers include genetic influence, hormonal influence, and ultraviolet radiation. Due to the avoidance of ultraviolet light, vitamin D supplementation is recommended. Due to known influence of vitamin D on the skin and the large prevalence of melasma in the public, the association between vitamin D and melasma will be examined further.\u0000Methods\u0000A retrospective review was performed utilizing the TriNetX platform to query de-identified patient data from the Medical University of South Carolina’s Electronic Health Record system over a 9-year period from January 2013 to May 2022. Calcidiol (25-hydroxy-vitaminD) was utilized as a surrogate for Vitamin D level. Statistical analyses were performed using Chi-square tests.\u0000Results\u0000Of 1,962 patients diagnosed with melasma, 840 had a serum calcidiol level measured following diagnosis. The majority of these patients were female (77%) and had an average age of 60.3 + 19.2 years. Melasma patients were most commonly Caucasian (81%), followed by African American (15%) and Hispanic or Latino (3%). Patients with melasma had an average serum calcidiol of 33.8 + 15.8 ng/mL (reference range: 25 – 80 ng/mL). This was significantly lower than comparison to 2,146 dermatology patients not diagnosed with melasma (36.8 + 15.8 ng/mL, p-value <0.0001%). \u0000Conclusion\u0000Vitamin D has been demonstrated to be critical in the skin, including differentiation and proliferation of melanocytes. Our results suggest that patients with melasma, who have significantly lower levels of serum vitamin D than their healthy counterparts, may benefit from vitamin D supplementation. Future studies investigating improvement in melasma symptoms following vitamin D supplementation are needed.","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43248417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Arthur M Samia, F. Lacy, Sam Wu, Carolyn M. Ziemer
{"title":"Total Skin Electron Beam Therapy-Induced Erythrodermic Subacute Radiation Dermatitis in a 54-Year-Old Man with Underlying Cutaneous T-Cell Lymphoma","authors":"Arthur M Samia, F. Lacy, Sam Wu, Carolyn M. Ziemer","doi":"10.25251/skin.7.3.18","DOIUrl":"https://doi.org/10.25251/skin.7.3.18","url":null,"abstract":"","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42507543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-20DOI: 10.25251/skin.7.supp.209
E. Graber, H. Baldwin, A. Alexis, J. D. Del Rosso, R. Fried, J. Harper, Adelaide Hebert, L. Kircik, E. Rieder, L. Stein Gold, Siva Narayanan, V. Koscielny, I. Kasujee
Introduction: The objective of this analysis was to evaluate clinician satisfaction with treatment outcomes, stratified by the use of concomitant acne medications, among AV patients administered sarecycline in community practices across the U.S. Methods: A single-arm, prospective cohort study (PROSES) was conducted with moderate-to-severe non-nodular AV patients >9 years who were prescribed sarecycline in real-world community practices in the US. Clinician satisfaction with sarecycline treatment outcomes was assessed on a five-point adjectival response scale (1 (very dissatisfied)-5 (very satisfied)). Proportion of patients for whom clinicians reported very satisfied/satisfied was analyzed, stratified by the use of any concomitant AV medication during the study (Yes vs. No (monotherapy)). Results: A total of 253 AV patients completed the study (adults 60.08% (mean age 26.63); pediatric 39.92% (mean age 14.81); female: 66.40%; white/Caucasian: 68.38%, African American: 8.70%; other races: 22.92%). Per IGA at baseline, 86.56% & 13.44% had moderate and severe AV, respectively. Key concomitant treatments for AV observed during the study included: topical retinoids (24.51%), topical antibiotics (13.44%), benzoyl peroxide (5.93%), topical dapsone (5.14%) and other (17.00%; predominantly adapalene/benzoyl peroxide). Half of the patients (49.80%) were on sarecycline monotherapy (i.e., did not use any concomitant treatments for AV). In the overall study cohort, at week-12, clinicians reported very satisfied/satisfied with sarecycline treatment outcomes for 88.14% of patients. At week-12, clinician satisfaction (very satisfied/satisfied) was 88.98% among patients using concomitant AV medications, and 87.30% among patients using no concomitant AV medications (i.e., on sarecycline monotherapy). Conclusion: Within the study cohort administered sarecycline, a narrow-spectrum, tetracycline-derived antibiotic, for 12 weeks, overwhelming majority of clinicians were very satisfied/satisfied with sarecycline treatment outcomes at week-12, and clinician satisfaction was similar among patients on sarecycline monotherapy and those on concomitant AV medications.
{"title":"Clinician satisfaction with treatment outcomes among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in community practices across the U.S in PROSES study: Analysis by concomitant medication use","authors":"E. Graber, H. Baldwin, A. Alexis, J. D. Del Rosso, R. Fried, J. Harper, Adelaide Hebert, L. Kircik, E. Rieder, L. Stein Gold, Siva Narayanan, V. Koscielny, I. Kasujee","doi":"10.25251/skin.7.supp.209","DOIUrl":"https://doi.org/10.25251/skin.7.supp.209","url":null,"abstract":"Introduction: The objective of this analysis was to evaluate clinician satisfaction with treatment outcomes, stratified by the use of concomitant acne medications, among AV patients administered sarecycline in community practices across the U.S. \u0000Methods: A single-arm, prospective cohort study (PROSES) was conducted with moderate-to-severe non-nodular AV patients >9 years who were prescribed sarecycline in real-world community practices in the US. Clinician satisfaction with sarecycline treatment outcomes was assessed on a five-point adjectival response scale (1 (very dissatisfied)-5 (very satisfied)). Proportion of patients for whom clinicians reported very satisfied/satisfied was analyzed, stratified by the use of any concomitant AV medication during the study (Yes vs. No (monotherapy)). \u0000Results: A total of 253 AV patients completed the study (adults 60.08% (mean age 26.63); pediatric 39.92% (mean age 14.81); female: 66.40%; white/Caucasian: 68.38%, African American: 8.70%; other races: 22.92%). Per IGA at baseline, 86.56% & 13.44% had moderate and severe AV, respectively. Key concomitant treatments for AV observed during the study included: topical retinoids (24.51%), topical antibiotics (13.44%), benzoyl peroxide (5.93%), topical dapsone (5.14%) and other (17.00%; predominantly adapalene/benzoyl peroxide). Half of the patients (49.80%) were on sarecycline monotherapy (i.e., did not use any concomitant treatments for AV). \u0000In the overall study cohort, at week-12, clinicians reported very satisfied/satisfied with sarecycline treatment outcomes for 88.14% of patients. At week-12, clinician satisfaction (very satisfied/satisfied) was 88.98% among patients using concomitant AV medications, and 87.30% among patients using no concomitant AV medications (i.e., on sarecycline monotherapy). \u0000Conclusion: Within the study cohort administered sarecycline, a narrow-spectrum, tetracycline-derived antibiotic, for 12 weeks, overwhelming majority of clinicians were very satisfied/satisfied with sarecycline treatment outcomes at week-12, and clinician satisfaction was similar among patients on sarecycline monotherapy and those on concomitant AV medications.","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48506262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Raquel Wescott, Ramneek K Dhami, Lingchen Wang, W. Hovenic
Introduction: TikTok is a popular social media platform that is sometimes used to share medical information. 1 Creators share their experiences with or provide education regarding medical diagnoses. This study investigated the content quality of TikTok videos regarding hidradenitis suppurativa (HS). Methods: On October 24, 2022, we searched #hidradenitissuppurativa on TikTok and filtered by most liked videos. Two independent reviewers analyzed the videos, excluding those not in English, irrelevant to HS, and duplicates. Videos were scored using the Global Quality Scale (GQS), 2 a one question scale (1-poor quality to 5-excellent quality), and the DISCERN tool, 3 a 16-question analysis (1-low quality to 5-high quality). Results: One-hundred videos were included. The mean GQS score was 2.49 [SD 0.87] and mean DISCERN score was 1.98 [SD 0.52], with substantial interrater reliability (Cohen’s Kappa 0.667). Twenty-six videos (26%) were created by physicians and 74 (74%) were created by non-physicians. Mean GQS and DISCERN scores for physician versus non-physician videos were 3.40 and 2.62, and 2.16 and 1.75, respectively. Both GQS and DISCERN scores were greater for videos created by physicians versus non-physicians (p < 0.0001). Conclusion: Overall, there is a lack of information on treatment benefits, risks, and mechanism of action. Given the mean GQS and DISCERN scores, the average video was of generally poor quality, creating potential for lack of knowledge and misinformation regarding HS. With the growing use of TikTok for educational purposes, improving content quality should be a priority to provide accurate information regarding medical conditions such as HS.
{"title":"Hidradenitis Suppurativa: A Cross-sectional Study of Content Quality on TikTok","authors":"Raquel Wescott, Ramneek K Dhami, Lingchen Wang, W. Hovenic","doi":"10.25251/skin.7.3.7","DOIUrl":"https://doi.org/10.25251/skin.7.3.7","url":null,"abstract":"Introduction: TikTok is a popular social media platform that is sometimes used to share medical information. 1 Creators share their experiences with or provide education regarding medical diagnoses. This study investigated the content quality of TikTok videos regarding hidradenitis suppurativa (HS).\u0000Methods: On October 24, 2022, we searched #hidradenitissuppurativa on TikTok and filtered by most liked videos. Two independent reviewers analyzed the videos, excluding those not in English, irrelevant to HS, and duplicates. Videos were scored using the Global Quality Scale (GQS), 2 a one question scale (1-poor quality to 5-excellent quality), and the DISCERN tool, 3 a 16-question analysis (1-low quality to 5-high quality).\u0000Results: One-hundred videos were included. The mean GQS score was 2.49 [SD 0.87] and mean DISCERN score was 1.98 [SD 0.52], with substantial interrater reliability (Cohen’s Kappa 0.667). Twenty-six videos (26%) were created by physicians and 74 (74%) were created by non-physicians. Mean GQS and DISCERN scores for physician versus non-physician videos were 3.40 and 2.62, and 2.16 and 1.75, respectively. Both GQS and DISCERN scores were greater for videos created by physicians versus non-physicians (p < 0.0001).\u0000Conclusion: Overall, there is a lack of information on treatment benefits, risks, and mechanism of action. Given the mean GQS and DISCERN scores, the average video was of generally poor quality, creating potential for lack of knowledge and misinformation regarding HS. With the growing use of TikTok for educational purposes, improving content quality should be a priority to provide accurate information regarding medical conditions such as HS.","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48103002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Schlesinger, L. Kircik, J. D. Del Rosso, D. Rigel, M. Lebwohl, B. Berman, A. Armstrong, N. Bhatia, Vishal Patel, Siva Narayanan, V. Koscielny, I. Kasujee
Background: Patients' experiences regarding topical actinic keratosis (AK) treatments may optimize clinical outcomes. PROAK study aimed to evaluate patient- and clinician-reported outcomes among adult patients with AK on face or scalp who were prescribed tirbanibulin in real-world clinical practice in the United States. Methods: Key primary endpoint was quality of life (QoL) assessed by Skindex-16. Additional endpoints were tirbanibulin treatment effectiveness and satisfaction (Treatment Satisfaction Questionnaire for Medication and Expert Panel Questionnaire). Results: 290 patients were included in this analysis. At week 8, Skindex-16 scores improved in all domains (mean change from baseline [standard deviation, SD]: -14.3 [27.8] in symptoms, -24.9 [33.0] in emotions, and -9.8 [23.7] in functioning domain). Clinicians and patients reported high global satisfaction with tirbanibulin (mean [SD] scores of 78.8 [20.1] and of 74.5 [23.5]). Overall skin appearance improved from baseline to week 8 (91.0% clinicians; 84.1% patients). In comparison with previous treatments, tirbanibulin had shorter skin reactions duration (89.2% clinicians; 73.9% patients); milder skin reaction severity (91.0% clinicians; 76.6% patients); better daily activities impact (87.4% clinicians; 64.0% patients); and was easier to use (88.3% clinicians; 71.2% patients). Investigator’s Global Assessment (IGA) success (0-1) was achieved by 73.8% of the patients. Skin photodamage severity reduction from baseline to week 8 was significant (77.4% vs. 39.6%; p<0.0001). Conclusions: Tirbanibulin treatment demonstrated effectiveness in AK management. Moreover, tirbanibulin improved QoL, as early as week 8, and both clinicians and patients reported tirbanibulin treatment convenience, and high levels of treatment satisfaction, compared to patient’s previous treatments.
{"title":"Clinician- and Patient-Reported Outcomes with Tirbanibulin 1% Treatment for Actinic Keratosis in Routine Clinical Practice Across the U.S. (PROAK Study)","authors":"T. Schlesinger, L. Kircik, J. D. Del Rosso, D. Rigel, M. Lebwohl, B. Berman, A. Armstrong, N. Bhatia, Vishal Patel, Siva Narayanan, V. Koscielny, I. Kasujee","doi":"10.25251/skin.7.3.3","DOIUrl":"https://doi.org/10.25251/skin.7.3.3","url":null,"abstract":"Background: Patients' experiences regarding topical actinic keratosis (AK) treatments may optimize clinical outcomes. PROAK study aimed to evaluate patient- and clinician-reported outcomes among adult patients with AK on face or scalp who were prescribed tirbanibulin in real-world clinical practice in the United States. \u0000Methods: Key primary endpoint was quality of life (QoL) assessed by Skindex-16. Additional endpoints were tirbanibulin treatment effectiveness and satisfaction (Treatment Satisfaction Questionnaire for Medication and Expert Panel Questionnaire). \u0000Results: 290 patients were included in this analysis. At week 8, Skindex-16 scores improved in all domains (mean change from baseline [standard deviation, SD]: -14.3 [27.8] in symptoms, -24.9 [33.0] in emotions, and -9.8 [23.7] in functioning domain). Clinicians and patients reported high global satisfaction with tirbanibulin (mean [SD] scores of 78.8 [20.1] and of 74.5 [23.5]). Overall skin appearance improved from baseline to week 8 (91.0% clinicians; 84.1% patients). In comparison with previous treatments, tirbanibulin had shorter skin reactions duration (89.2% clinicians; 73.9% patients); milder skin reaction severity (91.0% clinicians; 76.6% patients); better daily activities impact (87.4% clinicians; 64.0% patients); and was easier to use (88.3% clinicians; 71.2% patients). Investigator’s Global Assessment (IGA) success (0-1) was achieved by 73.8% of the patients. Skin photodamage severity reduction from baseline to week 8 was significant (77.4% vs. 39.6%; p<0.0001). \u0000Conclusions: Tirbanibulin treatment demonstrated effectiveness in AK management. Moreover, tirbanibulin improved QoL, as early as week 8, and both clinicians and patients reported tirbanibulin treatment convenience, and high levels of treatment satisfaction, compared to patient’s previous treatments.","PeriodicalId":74803,"journal":{"name":"Skin (Milwood, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49360442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：